Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | PDE1A | P54750 | 1/20 | 0.47 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | GPR6 | P46095 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.41 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.41 |
| ▸ | PDE9A | O76083 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29844280 | 0.96 | KDM4E (0.47) | KDM4EPDE5APDE1APDE1BPDE1C | |
| SCHEMBL23761235 | 0.92 | EPHX2 (0.44) | KDM4EPDE5APDE1APDE1BPDE1C | |
| SCHEMBL30505244 | 0.92 | EPHX2 (0.44) | KDM4EPDE5APDE1APDE1BPDE1C | |
| Hydrochloric Acid SCHEMBL25401967 | 0.91 | EPHX2 (0.44) | KDM4EPDE5APDE1APDE1BPDE1C | |
| SCHEMBL12284287 | 0.84 | SLC6A2 (0.42) | KDM4EPDE5APDE1APDE1BPDE1C | |
| SCHEMBL16989684 | 0.84 | TRPC3 (0.44) | KDM4EPDE5APDE1APDE1BPDE1C | |
| SCHEMBL3128288 | 0.84 | GPR6 (0.42) | KDM4EEPHX2XDHGPR6POLB | |
| SCHEMBL4120430 | 0.84 | HRH1 (0.57) | — | |
| SCHEMBL16989683 | 0.84 | TRPC3 (0.44) | KDM4EPDE5APDE1APDE1BPDE1C | |
| SCHEMBL1667102 | 0.84 | TBK1 (0.49) | PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | KDM4E 4678/4885PDE5A 160/4885PDE1A 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.